Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Novo Nordisk's continued dominance in this field ... The company recently reported positive phase 3 results for Mim8 in patients with hemophilia. It has products across several other fields ...

NovoCare also lists Novo Nordisk diabetes products as well as the pharma giant’s drugs for growth-related disorders, hemophilia, and hyperoxaluria. “Today, over 55 million people in the U.S ...

Citing that there is unmet medical need in the country for the proposed indication, the Subject Expert Committee (SEC) ...